Drupal.behaviors.print = function(context) {window.print();window.close();}>
Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011
Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor
Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter
Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013 / Pharmacogenomics Reporter
Boehringer Launches 'Let's Test' Campaign to Educate Healthcare Providers on NSCLC Biomarker Testing
October 24, 2012 / Pharmacogenomics Reporter
During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter